As far as safety in pregnancy is concerned, the current classification of anti-hepatitis B virus drugs is as follows: 1. Lamivudine and telbivudine are classified as Class B. These drugs can be used for treatment during pregnancy if it is convinced that the potential therapeutic benefit outweighs the potential risk to the mother and the fetus. 2. Entecavir and adefovir are classified as Class C. Because of the toxicity to the embryo and fetus observed in animals, these two drugs are not recommended for use during pregnancy. 3. Interferon alpha is classified as Class D. Animal studies have shown reproductive toxicity of this product. Recommendations for anti-HBV treatment in women of childbearing age: Preconception anti-HBV treatment: meeting the antiviral criteria, it is recommended to first choose interferon therapy for at least one year and 6 months after the end of the course, pregnancy is possible. Next consider lamivudine and also consider tibivudine. Pregnancy can be considered after 3 to 6 months of treatment and after antiviral efficacy is achieved. Anti-HBV therapy during pregnancy: When anti-HBV therapy is needed after pregnancy in women who meet antiviral criteria, lamivudine or telbivudine may be used, provided that the patient and family give full informed consent and that monitoring is intensified. Those who attempt to become pregnant during treatment should immediately discontinue the drug and abort the pregnancy if they become pregnant accidentally while taking entecavir or adefovir; those who continue the pregnancy should be closely monitored for fetal development. Treatment may also be continued by switching to a class B drug such as lamivudine or telbivudine. Antiviral drugs should not be used in breastfeeding women as much as possible. If necessary, lamivudine or telbivudine is recommended. If other antiviral drugs are required, it is recommended to stop breastfeeding.